AIM ImmunoTech Inc
AIM3.040USD
+0.210+7.42%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
219.76MCap. mercado
PérdidaP/E TTM
Más Datos de AIM ImmunoTech Inc Compañía
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Información de la empresa
Símbolo de cotizaciónAIM
Nombre de la empresaAIM ImmunoTech Inc
Fecha de salida a bolsaJul 12, 1996
Director ejecutivoMr. Thomas K. Equels, Esq., J.D.
Número de empleados21
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 12
Dirección2117 Sw Highway 484
CiudadOCALA
Bolsa de valoresNYSE American Consolidated
PaísUnited States of America
Código postal32801
Teléfono13524487797
Sitio Webhttps://aimimmuno.com/
Símbolo de cotizaciónAIM
Fecha de salida a bolsaJul 12, 1996
Director ejecutivoMr. Thomas K. Equels, Esq., J.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
38.88K
+0.54%
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
19.70K
+196850.00%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
+60.53%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
+31.96%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
642.00
+232.64%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
38.88K
+0.54%
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
19.70K
+196850.00%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
+60.53%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
+31.96%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
642.00
+232.64%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 12 de jul
Actualizado: sáb., 12 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Equels (Thomas K)
1.41%
The Vanguard Group, Inc.
0.88%
Kellner (Theodore D)
0.71%
Deutsch (Todd A)
0.62%
BlackRock Institutional Trust Company, N.A.
0.25%
Other
96.12%
Accionistas
Accionistas
Proporción
Equels (Thomas K)
1.41%
The Vanguard Group, Inc.
0.88%
Kellner (Theodore D)
0.71%
Deutsch (Todd A)
0.62%
BlackRock Institutional Trust Company, N.A.
0.25%
Other
96.12%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
12.10%
Investment Advisor
4.36%
Investment Advisor/Hedge Fund
1.03%
Hedge Fund
0.74%
Venture Capital
0.11%
Other
81.65%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
68
140.24K
18.35%
-21.39K
2025Q1
83
99.85K
13.13%
-1.64M
2024Q4
79
10.59M
16.61%
-4.59M
2024Q3
75
14.47M
24.79%
+767.12K
2024Q2
74
13.00M
23.76%
+4.07M
2024Q1
77
8.58M
17.30%
-354.68K
2023Q4
77
8.35M
17.07%
-576.60K
2023Q3
80
8.49M
17.46%
-718.46K
2023Q2
77
5.43M
11.23%
-869.40K
2023Q1
81
5.73M
11.83%
-1.19M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Equels (Thomas K)
38.88K
5.09%
+210.00
+0.54%
Jun 13, 2025
The Vanguard Group, Inc.
24.44K
3.2%
+4.56K
+22.91%
Mar 31, 2025
Kellner (Theodore D)
19.70K
2.58%
+19.68K
+196850.00%
Apr 11, 2025
Deutsch (Todd A)
17.16K
2.25%
--
--
Dec 19, 2024
BlackRock Institutional Trust Company, N.A.
6.98K
0.91%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
5.31K
0.7%
+673.00
+14.50%
Mar 31, 2025
Mitchell (William M)
5.22K
0.68%
+1.97K
+60.53%
Apr 11, 2025
Rodino (Peter W III)
4.02K
0.53%
+5.00
+0.12%
Apr 04, 2025
Appelrouth (Stewart L.)
3.89K
0.51%
+670.00
+20.82%
Dec 31, 2024
Renaissance Technologies LLC
3.18K
0.42%
+575.00
+22.07%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Mar 03, 2025
Merger
100<1
Fecha
Tipo
Relación
Mar 03, 2025
Merger
100<1
